1. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
- Author
-
Emily Glowienka, Yingxin Xu, Florence Wilson, Patricia Guyot, Sam Keeping, Kokuvi Atsou, Meena Venkatachalam, Caitlin Smare, Chieh-I Chen, Andreas Kuznik, Gerasimos Konidaris, and Keith Syson Chan
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Standard of care ,Cost effectiveness ,Cost-Benefit Analysis ,medicine.medical_treatment ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,B7-H1 Antigen ,law.invention ,Antineoplastic Agents, Immunological ,Randomized controlled trial ,law ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Lung cancer ,Chemotherapy ,business.industry ,Health Policy ,Hazard ratio ,Public Health, Environmental and Occupational Health ,Standard of Care ,Middle Aged ,medicine.disease ,Progression-Free Survival ,United States ,Survival Rate ,Quality-Adjusted Life Years ,Non small cell ,business - Abstract
Objectives This study aimed to evaluate the cost-effectiveness, from a US commercial payer perspective, of cemiplimab versus other first-line treatments for advanced non-small cell lung cancer with programmed death-ligand 1 expression ≥50%. Methods A 30-year “partitioned survival” model was constructed. Overall survival and progression-free survival were estimated by applying time-varying hazard ratios from a network meta-analysis of randomized clinical trials. Overall survival and progression-free survival were estimated from EMPOWER-Lung 1 (cemiplimab monotherapy vs chemotherapy) and KEYNOTE-024 and KEYNOTE-042 (pembrolizumab monotherapy vs chemotherapy). Drug acquisition costs were based on published 2020 US list prices. A 3% discount rate was applied to life-years, quality-adjusted life-years (QALYs), and costs. A deterministic analysis was performed on the base case; 1-way sensitivity and probabilistic sensitivity analyses assessed model and parameter uncertainties. Results Cemiplimab was associated with increased time in the “preprogression” (13.08 vs 7.90 and 6.08 months) and “postprogression” (47.30 vs 29.49 and 14.78 months) health states versus pembrolizumab and chemotherapy, respectively. Compared with pembrolizumab and chemotherapy, cemiplimab generated 1.00 (95% CI −0.266 to 2.440) and 1.78 (95% CI 0.607-3.20) incremental QALYs, respectively, with incremental cost-effectiveness ratios of $68 254 and $89 219 per QALY for cemiplimab versus pembrolizumab and cemiplimab versus chemotherapy, respectively. The probability of cemiplimab being cost-effective at a willingness-to-pay threshold of $100 000 to $150 000 per QALY was 62% to 76% versus pembrolizumab and 56% to 84% versus chemotherapy. Conclusions Findings suggest that cemiplimab, versus pembrolizumab or versus chemotherapy, is a cost-effective first-line treatment option for advanced non-small cell lung cancer with programmed death-ligand 1 expression ≥50%.
- Published
- 2022
- Full Text
- View/download PDF